DOCSLIB.ORG

Peptide Handbook a Guide to Peptide Design and Applications in Biomedical Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Peptide Handbook a Guide to Peptide Design and Applications in Biomedical Research Peptide Handbook A Guide to Peptide Design and Applications in Biomedical Research First Edition www.GenScript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 USA Phone: 1-732-885-9188 Toll-Free: 1-877-436-7274 Fax: 1-732-885-5878 Table of Contents The Universe of Peptides Reliable Synthesis of High-Quality Peptides Molecular structure 3 by GenScript Characteristics 5 Categories and biological functions 8 Analytical methods 10 Application of Peptides Research in structural biology 12 Research in disease pathogenesis 12 Generating antibodies 13 FlexPeptideTM Peptide Synthesis Platform which takes advantage of the latest Vaccine development 14 peptide synthesis technologies generates a large capacity for the quick Drug discovery and development 15 synthesis of high-quality peptides in a variety of lengths, quantities, purities Immunotherapy 17 and modifications. Cell penetration-based applications 18 Anti-microorganisms applications 19 Total Quality Management System based on multiple rounds of MS and HPLC Tissue engineering and regenerative medicine 20 analyses during and after peptide synthesis ensures the synthesis of Cosmetics 21 high-quality peptides free of contaminants, and provides reports on peptide Food industry 21 solubility, quality and content. Synthesis of Peptides Diverse Delivery Options help customers plan their peptide-based research Chemical synthesis 23 according to their time schedule and with peace of mind. Microwave-assisted technology 24 ArgonShield™ Packing eliminates the experimental variation caused by Ligation technology 26 oxidization and deliquescence of custom peptides through an innovative Recombinant technology 28 Modifications packing and delivery technology. 28 Purification 30 Expert Support offered by Ph.D.-level scientists guides customers from Product identity and quality control 31 peptide design and synthesis to reconstitution and application. Reconstitution, storage and handling 32 Delivery formats 34 Considerations in peptide design 35 Future of Peptides 38 Resources on Peptides Peptide-related tools 40 Troubleshooting guide 41 References 44 https://www.genscript.com/peptide-services.html https://www.genscript.com/peptide-handbook.html 1 Molecular Structure The word peptide, derived from the Greek word“peptós/digested,” refers to a chain of amino acids (AAs) linked together via amide or peptide bonds. The formation of the covalent peptide bond is an example of a condensation reaction, which generates water from the combination of the α-carboxyl group of one AA and the α-amino group of another. An AA unit within a peptide chain is called a "residue”. A peptide can be as short as two residues with only one peptide bond (named “dipeptide”) or as long as several residues forming a continuous and unbranched peptide chain (named “oligo- peptide” if containing <20 AAs or polypeptide if containing >20 AAs). Proteins are comprised of many peptide chains and sometimes the terms “polypeptide” and “protein” are used interchangeably. There are several different conventions for making a distinction between the two, but in general, molecules referred to as polypeptides have molecular weights (MWs) below 10,000 Daltons or less than 50 Chapter One AAs, and molecules above these limits are considered as proteins (Lehninger et al.) Peptide Bond Formation The Universe of Peptides Amino Acid 1 Amino Acid 2 R R H O N H H O H N H H O H H O Dipeptide Water R O H H H H N H O N O H H H O R Peptide Bond 3 In a peptide chain, the AA at the end with a free α-amino group is called the “amino-ter- minal” (N-terminal) residue, whereas the one at the other end with a free carboxyl group Characteristics is called the “carboxyl-terminal” (C-terminal) residue. The backbone carbon before the carboxyl carbon in an AA is called the “alpha carbon” (Cα) or “chiral center”, where differ- ent side chains attach. Depending on the position of carbon atoms relative to Cα, the remaining carbons are named with Greek letters of β, γ, etc. Numbering Carbon Atoms in an AA Each peptide has its own unique structural and biochemical characteristics, such as an isoelectric pH (pI) and ionization behavior. These features are derived from the peptide’s AA components. Therefore, the overall characteristics of a peptide can change depending γ ε δ β α on the quantity and type of each AA within the chain. 6 5 4 3 2 1 For example, the acid-base behavior of a peptide is defined by the nature of the free CH CH CH CH CH COO- 2 2 2 2 and bound AAs in its chain. The terminal α-amino and α-carboxyl groups sitting at opposite ends of the chain as well as the side chains (R groups) of some AAs can ionize and affect the + NH + NH 3 3 titration curve. Similarly, due to the positioning of the chiral carbon and stereoisomer configurations in all AAs except Glycine, the newly formed L or D isomer of AAs can add to Due to the possibility of forming two different enantiomers (stereoisomers) around their unique characteristics. Ultimately all these characteristics influence how a given the central carbon atom, all AAs except Glycine can exist in two isomeric configurations peptide behaves in a biological system. of D (dextrorotatory; right-handed) and L (levorotatory; left-handed). Until recently, most AAs synthesized by eukaryotes were reported to be in the L-isoform, whereas Formation of Acid or Base from an Amino Acid D-isoforms were predominantly found in bacterial cell wall proteins or synthesized chemically. However, due to latest developments in sensitive analytical methods, free D-amino acids are shown to be present in the nervous system and venom of animals as O O well (Kiriyama & Nochi). R + R OH H OH NH2 NH + Amino Acid Chirality 3 Positive Ion In acidic conditions: acting like a base. O O OH OH O O NH2 NH2 R - R 2 OH OH O- H O NH2 L-alanine D-alanine NH2 Negative Ion In basic conditions: acting like an acid. 4 5 Common Amino Acids Secondary Structure of Peptides O O O H OH OH OH OH H C H2N NH2 H NH2 NH2 N C O N C C O Alanine Isoleucine Leucine Valine C A I L V H O MW: 89.09 MW: 131.17 MW: 131.17 MW: 117.15 C H IP: 6.00 IP: 5.94 IP: 5.98 IP: 5.96 N C O C N H N O H C O O H H N OH OH 2 N C NH2 OH C NH2 N C NH2 HO O NH2 O OH C O H O Phenylalanine Tryptophan Tyrosine Asparagine C H F W Y N N C MW: 165.19 MW: 204.23 MW: 181.19 MW: 132.12 O C N IP: 5.48 IP: 5.89 IP: 5.66 IP: 5.41 H H C N C O O O O O N C S C OH O HS OH H2N OH HO OH C O NH2 NH2 NH2 H NH2 C H N C C Cysteine C Glutamine Q Methionine M Serine S O N MW: 121.16 MW: 146.15 MW: 149.21 MW: 105.09 C IP: 5.02 IP: 5.65 IP: 5.74 IP: 5.68 O O OH O NH O H O N β-sheet α-helix OH H2N OH H2N N OH OH H N NH2 NH2 NH2 NH2 Threonine T Arginine R Histidine H Lysine K MW: 119.12 MW: 174.2 MW: 155.16 MW: 146.19 IP: 5.64 IP: 11.15 IP: 7.47 IP: 9.59 GenScript’s Peptide Calculator can help you determine the chemical formula and MW of your peptide of interest. O OO O HO OH OH N H2N HO OH OH O NH2 H NH2 O Aspartic Acid D Glutamic Acid E Proline P Glycine G MW: 133.1 MW: 147.13 MW: 115.13 MW: 75.07 IP: 2.77 IP: 3.22 IP: 6.30 IP: 5.97 Aliphatic amino acids with hydrophobic side chain Amino acids with positive charged side chain Aromatic amino acids with hydrophobic side Chain Amino acids with negative charged side chain Amino acids with neutral side chain Unique amino acids MW: Molecular Weight IP: Isoelectric Point 66 7 The intrinsic characteristics of natural peptides, such as instability and proteolytic degra- Categories and Biological Functions dation limit their medicinal application. To overcome this limitation peptide analogues or “peptidomimetics” have been developed to mimic the biological actions of peptides without undesired restrictions (Olson). Peptidomimetics are synthesized by modification of an existing natural peptide or through introducing novel structural changes that render resistance to proteolytic degradation, increase thermodynamic stability and provide the capability to pass through the plasma membrane. The 7,000 naturally-occurring peptides are present in all organisms and have extensive roles in the physiology of microorganisms, plants, animals, and humans. To better study and use peptides, they can be classified using different methods. The function of peptides Peptide vs Peptidomimetics as hormones, growth factors, ion channel ligands, neurotransmitters, and immune system components in biological systems is the basis of one method of peptide classification. O R' R O Another approach is based on the way natural peptides are produced. Each method of H classification may overlap with another and can be field or application specific. N OH N OH H N H N H R' R O O Major Classes of Peptides n n Peptide Peptoid Class Source Application/Function O O H N N OH Antibiotics, Hormones, R' Ribosomal Peptides mRNA translation R Signaling peptides, Bacteriocins n β-Peptoid Toxins, Cytostatics, Sidero- Non-ribosomal peptide phores, Pigments, Antibiotics, Non-Ribosomal Peptides synthetases Immunosuppressants R O R' O O R' O H H N Enzymatic digestion or N N OH Ingredient in bacteria and H N OH Peptones acid hydrolysis of natural H H fungal growth media R R products n n β3-Peptoid β2-Peptoid Enzymatic degradation of laboratory samples Adapted from Olson, 2010.
Load more

Recommended publications
  • A Comparative Survey of the RF-Amide Peptide Superfamily
    EDITORIAL published: 10 August 2015 doi: 10.3389/fendo.2015.00120 Editorial: A comparative survey of the RF-amide peptide superfamily Karine Rousseau 1*, Sylvie Dufour 1 and Hubert Vaudry 2 1 Laboratory of Biology of Aquatic Organisms and Ecosystems (BOREA), Muséum National d’Histoire Naturelle, CNRS 7208, IRD 207, Université Pierre and Marie Curie, UCBN, Paris, France, 2 Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U982, International Associated Laboratory Samuel de Champlain, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Mont-Saint-Aignan, France Keywords: RF-amide peptides, receptors, evolution, functions, deuterostomes, protostomes The first member of the RF-amide peptide superfamily to be characterized, in 1977, was the cardioexcitatory peptide, FMRFamide, isolated from the ganglia of the clam Macrocallista nimbosa (1). Since then, a large number of such peptides, designated after their C-terminal arginine (R) and amidated phenylalanine (F) residues, have been identified in representative species of all major phyla. The discovery, 12 years ago, that the RF-amide peptide kisspeptin, acting via GPR54, was essential for the onset of puberty and reproduction, has been a major breakthrough in reproductive physiology (2–4). It has also put in front of the spotlights RF-amide peptides and has invigo- rated research on this superfamily of regulatory neuropeptides. The present Research Topic aims at illustrating major advances achieved, through comparative studies in (mammalian and non- mammalian) vertebrates and invertebrates, in the knowledge of RF-amide peptides in terms of evolutionary history and physiological significance. Since 2006, by means of phylogenetic analyses, the superfamily of RFamide peptides has been divided into five families/groups in vertebrates (5, 6): kisspeptin, 26RFa/QRFP, GnIH (including LPXRFa and RFRP), NPFF, and PrRP.
    [Show full text]
  • 6-[18 F] Fluoro-L-DOPA: a Well-Established Neurotracer with Expanding Application Spectrum and Strongly Improved Radiosyntheses
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 674063, 12 pages http://dx.doi.org/10.1155/2014/674063 Review Article 6-[18F]Fluoro-L-DOPA: A Well-Established Neurotracer with Expanding Application Spectrum and Strongly Improved Radiosyntheses M. Pretze,1 C. Wängler,2 and B. Wängler1 1 Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany 2 Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany Correspondence should be addressed to B. Wangler;¨ [email protected] Received 26 February 2014; Revised 17 April 2014; Accepted 18 April 2014; Published 28 May 2014 Academic Editor: Olaf Prante Copyright © 2014 M. Pretze et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 18 For many years, the main application of [ F]F-DOPA has been the PET imaging of neuropsychiatric diseases, movement disorders, and brain malignancies. Recent findings however point to very favorable results of this tracer for the imaging of other malignant diseases such as neuroendocrine tumors, pheochromocytoma, and pancreatic adenocarcinoma expanding its application spectrum. With the application of this tracer in neuroendocrine tumor imaging, improved radiosyntheses have been developed. Among these, 18 the no-carrier-added nucleophilic introduction of fluorine-18, especially, has gained increasing attention as it gives [ F]F-DOPA in higher specific activities and shorter reaction times by less intricate synthesis protocols.
    [Show full text]
  • Genscript Product Catalog 2013-2014 Genscript Product Catalog
    GenScript Product Catalog 2013-2014 GenScript Product Catalog www.genscript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854USA Tel: 1-732-885-9188 / 1-732-885-9688 Toll-Free Tel: 1-877-436-7274 Fax: 1-732-210-0262 / 1-732-885-5878 Email: [email protected] Nucleic Acid Purification and Analysis Business Development Tel: 1-732-317-5088 PCR PCR and Cloning Email: [email protected] Protein Analysis Antibodies 2013-2014 Peptides Welcome to GenScript GenScript USA Incorporation, founded in 2002, is a fast-growing biotechnology company and contract research organization (CRO) specialized in custom services and consumable products for academic and pharmaceutical research. Built on our assembly-line mode, one-stop solutions, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of products and services at the most competitive prices in the industry to meet your research needs every day. Over the years, GenScript’s scientists have developed many innovative technologies that allow us to maintain our position at the cutting edge of biological and medical research while offering cost-effective solutions for customers to accelerate their research. Our advanced expertise includes proprietary technology for custom gene synthesis, OptimumGeneTM codon optimization technology, CloneEZ® seamless cloning technology, FlexPeptideTM technology for custom peptide synthesis, BacPowerTM technology for protein expression and purification, T-MaxTM adjuvant and advanced nanotechnology for custom antibody production, as well as our ONE-HOUR WesternTM detection system and eStain® protein staining system. GenScript offers a broad range of reagents, optimized kits, and system solutions to help you unravel the mysteries of biology. We also provide a comprehensive portfolio of customized services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,353,350 B2 Kobayashi Et Al
    US009353350B2 (12) United States Patent (10) Patent No.: US 9,353,350 B2 Kobayashi et al. (45) Date of Patent: May 31, 2016 (54) METHOD FOR PRODUCING MULTIPOLAR 2012fO149053 A1 6, 2012 Yoshida et al. CELL 2013,0323,776 A1 12/2013 Yoshida et al. 2015. OO18286 A1* 1/2015 Kobayashi et al. .......... 514, 19.3 (71) Applicant: TOAGOSEICO.,LTD., Tokyo (JP) FOREIGN PATENT DOCUMENTS (72) Inventors: Nahoko Kobayashi, Tsukuba (JP); CN 1763O82 A 4/2006 Tetsuhiko Yoshida, Tsukuba (JP); Yuki DE 102009021681 A1 11, 2010 Kobayashi, Fujisawa (JP) WO O3O24408 A2 3, 2003 WO O3O37172 A2 5, 2003 WO 2004.005472 A2 1, 2004 (73) Assignee: TOAGOSEICO. LTD., Tokyo (JP) WO 2004/020457 A2 3, 2004 WO 2007/004869 A2 1, 2007 (*) Notice: Subject to any disclaimer, the term of this WO 2007056188 A1 5/2007 patent is extended or adjusted under 35 WO 2008/081812 A1 T 2008 WO WO 2009,093692 A1 T 2009 U.S.C. 154(b) by 0 days. WO WO 2011/O13698 A1 2, 2011 (21) Appl. No.: 14/366,971 WO WO 2011/O13699 A1 2, 2011 (22) PCT Filed: Dec. 20, 2012 OTHER PUBLICATIONS Paradis-Bleau et al., “Peptide inhibitors of the essential cell division (86). PCT No.: PCT/UP2O12AO83110 protein FtsA'. Protein Engineering, Design & Selection, 2005, pp. S371 (c)(1), 85-91, vol. 18, No. 2, Oxford University Press. (2) Date: Jun. 19, 2014 Paradis-Bleau et al., “Identification of Pseudomonas aeruginosa FtsZ. peptide inhibitors as a tool for development of novel antimicro bials”, Journal of Antimicrobial Chemotherapy, Jun. 2004, pp.
    [Show full text]
  • TRH-Like Peptides
    Physiol. Res. 60: 207-215, 2011 https://doi.org/10.33549/physiolres.932075 REVIEW TRH-Like Peptides R. BÍLEK1, M. BIČÍKOVÁ1, L. ŠAFAŘÍK2 1Institute of Endocrinology, Prague, Czech Republic, 2Urology Clinic, Beroun, Czech Republic Received September 6, 2010 Accepted October 8, 2010 On-line November 29, 2010 Summary of the leaders working in the area concerning the TRH TRH-like peptides are characterized by substitution of basic research was Professor V. Schreiber from Prague, Czech amino acid histidine (related to authentic TRH) with neutral or Republic, which already in 1959 formulated the acidic amino acid, like glutamic acid, phenylalanine, glutamine, hypothesis that adenohypophyseal acid phosphatase is tyrosine, leucin, valin, aspartic acid and asparagine. The related to thyrotropin secretion and that TRH is its presence of extrahypothalamic TRH-like peptides was reported in possible activator (Schreiber and Kmentova 1959, peripheral tissues including gastrointestinal tract, placenta, neural Schreiber et al. 1962). TRH precursor, human prepro- tissues, male reproductive system and certain endocrine tissues. TRH, consists of 242 amino acid residues, and contains Work deals with the biological function of TRH-like peptides in six separate copies of the TRH progenitor sequence different parts of organisms where various mechanisms may (Satoh and Mori 1994), which determine the primary serve for realisation of biological function of TRH-like peptides as structure of TRH as a tripeptide pyroglutamyl-histidinyl- negative feedback to the pituitary exerted by the TRH-like proline amide. The transcriptional unit of prepro-TRH is peptides, the role of pEEPam such as fertilization-promoting localized on chromosome 3 in humans (three exons peptide, the mechanism influencing the proliferative ability of interrupted by two introns) (Yamada et al.
    [Show full text]
  • Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: a Pilot Dose-Ranging Study
    nutrients Article Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study Anne Christin Meyer-Gerspach 1,2,* , Jürgen Drewe 3, Wout Verbeure 4 , Carel W. le Roux 5, Ludmilla Dellatorre-Teixeira 5, Jens F. Rehfeld 6, Jens J. Holst 7 , Bolette Hartmann 7, Jan Tack 4, Ralph Peterli 8, Christoph Beglinger 1,2 and Bettina K. Wölnerhanssen 1,2,* 1 St. Clara Research Ltd. at St. Claraspital, 4002 Basel, Switzerland; [email protected] 2 Faculty of Medicine, University of Basel, 4001 Basel, Switzerland 3 Department of Clinical Pharmacology and Toxicology, University Hospital of Basel, 4001 Basel, Switzerland; [email protected] 4 Translational Research Center for Gastrointestinal Disorders, Catholic University of Leuven, 3000 Leuven, Belgium; [email protected] (W.V.); [email protected] (J.T.) 5 Diabetes Complications Research Centre, Conway Institute University College Dublin, 3444 Dublin, Ireland; [email protected] (C.W.l.R.); [email protected] (L.D.-T.) 6 Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 7 Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; [email protected] (J.J.H.); [email protected] (B.H.) 8 Department of Surgery, Clarunis, St. Claraspital, 4002 Basel, Switzerland; [email protected] * Correspondence: [email protected] (A.C.M.-G.); [email protected] (B.K.W.); Tel.: +41-61-685-85-85 (A.C.M.-G.
    [Show full text]
  • UK Automated Synthesis Forum 2017 Agenda
    “The primary showcase of chemical technologies since 1996” UK Automated Synthesis Forum 2017 Agenda Tuesday, 7th November 2017 10:00am Introductory Remarks Jason Tierney, Charles River, Chair UKASF 10:10am Welcome Remarks Paul Kendall, Festo 10:20am Plenary Lecture: Earth, Wind, Fire and Light - New Technologies Enabling Chemical Innovation Dr. Ian W Davies, Princeton 11:20am Coffee & Networking Metabolite Synthesis and purification Chair: Andrew Ledgard (Lilly) / Paul Blaney (Concept Life Sciences) 11:40am The Generation and Identification of Biosynthetic Metabolites Dr. Scott Martin and Dr. Eva Lenz, AstraZeneca 12:00pm Reaction Screening Tools for Medicinal Chemistry Marc Bazin, Hepatochem 12:20pm Challenges associated with small scale purification of metabolites and impurities Ronan Cleary, Waters Ltd 12.40pm Lunch, Exhibition & Networking Flow Chemistry I Chair: Paul Turner (AZ) / John Taylor (Beatson Institute) 2:30pm Using Open-Source Hardware and Software Technologies to Automate Chemical Synthesis Dr. Matthew O’Brien, University of Keele. 2:50pm Practical Organic Electrosynthesis in Laboratory Flow Electrolysis Cell with Extended Channels: Milligrammes to Multigrammes/Hour Prof. Richard Brown, University of Southampton 3:10pm Research towards Automated Continuous Flow Peptide Synthesis (Vapourtec) Dr. Nikzad Nikbin, New Path Molecular 3:30pm Photochemical reactors for both batch and flow Martyn Fordham, Asynt/Uniqsis 3:50-4:10pm Break New Technologies I Jason Tierney (Charles River) / Tobias Mochel (Sygnature Discovery) “The primary showcase of chemical technologies since 1996” 4:10pm What could be driving the lab of the future and is the ‘Smart Lab’ really a thing? Paul Kendall, Festo 4:30pm ElectraSyn 2.0: Facilitating the mass adoption of electrochemistry for preparative organic synthesis Kevin Mann, IKA 4:50pm Mya 4, the new Reaction Station from Radleys Dr.
    [Show full text]
  • Optimisation of Synthesis, Purification and Reformulation of (R)-[N-Methyl-11C]PK11195 for in Vivo PET Imaging Studies
    Optimisation of Synthesis, Purification and Reformulation of (R)-[N-methyl-11C]PK11195 for In Vivo PET Imaging Studies Vítor Hugo Pereira Alves Integrated Master in Biomedical Engineering Physics Department Faculty of Sciences and Technology of University of Coimbra 2012 To my Parents, Optimisation of Synthesis, Purification and Reformulation of (R)-[N-methyl-11C]PK11195 for In Vivo PET Imaging Studies Vítor Hugo Pereira Alves Supervisor: Miguel de Sá e Sousa Castelo Branco Co-supervisor: Antero José Pena Afonso de Abrunhosa Dissertation presented to the Faculty of Sciences and Technology of the University of Coimbra to obtain a Master’s degree in Biomedical Engineering Physics Department Faculty of Sciences and Technology of University of Coimbra 2012 This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognize that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without proper acknowledgement. i Acknowledgments First of all, I would like to express my gratitude to Professor Antero Abrunhosa, for the opportunity given to carry out this work, for all the knowledge and for the full confidence. More than a project supervisor, he was a friend and excellent professor for his support and encouragement to reach the defined goals. To Professor Miguel Castelo-Branco, director of the Institute for Nuclear Sciences Applied to Health and also supervisor of this work for all support and interest in this project. To Professor Francisco Alves, I am grateful for his full availability to help, and for all the times that I asked for carbon-11.
    [Show full text]
  • Combined Approaches to the Synthesis and Study of Glycoproteins
    REVIEW Combined Approaches to the Synthesis and Study of Glycoproteins Gonc¸alo J. L. Bernardes†, Bastien Castagner‡, and Peter H. Seeberger†,* †Department of Biomolecular Systems, Max-Planck Institute of Colloids and Interfaces, Research Campus Golm, 14424 Potsdam, Germany, and ‡Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH Zu¨rich), Wolfgang-Pauli-Str. 10, 8093 Zu¨rich, Switzerland arbohydrates constitute a large and diverse class of biopolymers. For a long time the pri- ABSTRACT Carbohydrates are the basis for many therapeutic and diagnostic C mary role of carbohydrates in biology was strategies, yet the full potential of glycans in medicine has not been realized. The viewed as a source of energy or as an integral part of cel- study of the precise role of different carbohydrates, bound to either proteins or lip- lular structure. However, over recent decades, it has be- ids, is hampered by difficulties in accessing pure, well-defined glycoconjugates. come clear that the expression of complex carbohy- This Review highlights recent advances in glycobiology with a particular empha- drates in human cells is critical in the development and sis on oligosaccharide synthesis and conjugation techniques for the construction physiology of living systems (1−4). The mammalian gly- of homogeneous glycoconjugates. New methods for the study of proteinϪglycan come is thought to be complex, due to the inherent interactions such as carbohydrate arrays and in vivo visualization of glycosylation structural diversity of carbohydrate molecules (5). Na- pattern changes will also be addressed. The development of glycotherapeutics is ture uses this abundant repertoire of structures as spe- just beginning, and much remains to be understood about the relationship be- cific codes in several biological processes such as cellu- tween glycoconjugate structure and function.
    [Show full text]
  • What Is Pancreatic Polypeptide and What Does It Do?
    What is Pancreatic Polypeptide and what does it do? This document aims to evaluate current understanding of pancreatic polypeptide (PP), a gut hormone with several functions contributing towards the maintenance of energy balance. Successful regulation of energy homeostasis requires sophisticated bidirectional communication between the gastrointestinal tract and central nervous system (CNS; Williams et al. 2000). The coordinated release of numerous gastrointestinal hormones promotes optimal digestion and nutrient absorption (Chaudhri et al., 2008) whilst modulating appetite, meal termination, energy expenditure and metabolism (Suzuki, Jayasena & Bloom, 2011). The Discovery of a Peptide Kimmel et al. (1968) discovered PP whilst purifying insulin from chicken pancreas (Adrian et al., 1976). Subsequent to extraction of avian pancreatic polypeptide (aPP), mammalian homologues bovine (bPP), porcine (pPP), ovine (oPP) and human (hPP), were isolated by Lin and Chance (Kimmel, Hayden & Pollock, 1975). Following extensive observation, various features of this novel peptide witnessed its eventual classification as a hormone (Schwartz, 1983). Molecular Structure PP is a member of the NPY family including neuropeptide Y (NPY) and peptide YY (PYY; Holzer, Reichmann & Farzi, 2012). These biologically active peptides are characterized by a single chain of 36-amino acids and exhibit the same ‘PP-fold’ structure; a hair-pin U-shaped molecule (Suzuki et al., 2011). PP has a molecular weight of 4,240 Da and an isoelectric point between pH6 and 7 (Kimmel et al., 1975), thus carries no electrical charge at neutral pH. Synthesis Like many peptide hormones, PP is derived from a larger precursor of 10,432 Da (Leiter, Keutmann & Goodman, 1984). Isolation of a cDNA construct, synthesized from hPP mRNA, proposed that this precursor, pre-propancreatic polypeptide, comprised 95 residues (Boel et al., 1984) and is processed to produce three products (Leiter et al., 1985); PP, an icosapeptide containing 20-amino acids and a signal peptide (Boel et al., 1984).
    [Show full text]
  • CEM Peptide Synthesis Brochure
    Unparalleled Peptide Synthesis cempeptides.com Contents CEM Overview 2 Innovations in Microwave Peptide Synthesis 2 Founding Fathers 3 Corporate Legacy Chemistry Technologies 4 HE-SPPS 6 CarboMAXTM 8 One Pot Coupling/Deprotection Peptide Synthesizers 10 Sequential vs Parallel 11 Synthesizer Comparison 12 Discover BioTM 12 Liberty LiteTM 13 Liberty BlueTM 13 Liberty Blue HT12TM 14 Liberty PRIMETM 16 Accessories & Upgrades Peptide Cleavage 17 Razor® SPPS Reagents 18 Fmoc Amino Acids 19 Oxyma Pure 19 Resins (ProTide™, Polystyrene) Large Scale Microwave Peptide Synthesis 22 Liberty PRO™ Customers 24 Testimonials 25 Support CEM Overview Innovations in Microwave Peptide Synthesis 1978 CEM Corporation founded as a new company, based on microwave laboratory instrumentation 2001 CEM launches a single mode microwave system for chemical synthesis 2003 CEM develops the world’s first automated microwave peptide synthesizer1 2007 CEM publishes research for optimized methods for aspartimide formation and epimerization under microwave SPPS2 2013 Liberty Blue™ peptide synthesizer developed based on High Efficiency Solid Phase Peptide Synthesis (HE-SPPS) 2014 HE-SPPS methodology published3 2016 CEM launches new universal load resins eliminating the need for pre-loaded resins historically used 2016 CEM offers the world’s first large-scale microwave peptide synthesis, with capabilities of up to 500 grams of a purified peptide, in a single batch 2016 CEM develops improved carbodiimide coupling methods for peptide synthesis at elevated temperature (CarboMAX™) 2017 CEM develops a novel one-pot coupling/ deprotection process reducing SPPS cycle time and waste usage (Liberty PRIME™) Founding Fathers (circa 1980) Chemist: Dr. Michael J. Collins (Middle) Electrical Engineer: Ron Goetchius (Left) Mechanical Engineer: Bill Cruse Jr.
    [Show full text]
  • Rfamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential
    Pharmaceuticals 2011, 4, 1248-1280; doi:10.3390/ph4091248 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review RFamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential Maria Findeisen †, Daniel Rathmann † and Annette G. Beck-Sickinger * Institute of Biochemistry, Leipzig University, Brüderstraße 34, 04103 Leipzig, Germany; E-Mails: [email protected] (M.F.); [email protected] (D.R.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-341-9736900; Fax: +49-341-9736909. Received: 29 August 2011; in revised form: 9 September 2011 / Accepted: 15 September 2011 / Published: 21 September 2011 Abstract: Different neuropeptides, all containing a common carboxy-terminal RFamide sequence, have been characterized as ligands of the RFamide peptide receptor family. Currently, five subgroups have been characterized with respect to their N-terminal sequence and hence cover a wide pattern of biological functions, like important neuroendocrine, behavioral, sensory and automatic functions. The RFamide peptide receptor family represents a multiligand/multireceptor system, as many ligands are recognized by several GPCR subtypes within one family. Multireceptor systems are often susceptible to cross-reactions, as their numerous ligands are frequently closely related. In this review we focus on recent results in the field of structure-activity studies as well as mutational exploration of crucial positions within this GPCR system. The review summarizes the reported peptide analogs and recently developed small molecule ligands (agonists and antagonists) to highlight the current understanding of the pharmacophoric elements, required for affinity and activity at the receptor family.
    [Show full text]